Figure 1.

A multi-model approach to identify a clinically relevant biomarker for immunotherapy response

A schematic overview of the paper. (A and B) In brief, several mouse strains in combination with multiple cancer cell lines and clones were used to initially screen for and subsequently cross-validate a biomarker for immunotherapy response in mouse. (C) To clinically translate our findings, public data and data from a cohort of patients with non-small cell lung cancer (NSCLC) and skin cutaneous melanoma (SKCM) were used to assess the accuracy and utility of the identified biomarker in humans (see STAR Methods and introduction for additional, step-by-step details). Mouse strains: BALB/c, C57BL/6, and a C57BL/6 x CBA backcross. Cancer cell lines: 4T1 breast cancer, Lewis lung carcinoma (LLC), renal cell carcinoma (RENCA), and EMT6 breast cancer. P = parental cell line, M = mutagenized clone.